77 related articles for article (PubMed ID: 19698750)
1. Induction of complement-mediated lysis of HIV-1 by a combination of HIV-specific and HLA allotype-specific antibodies.
Hildgartner A; Wilflingseder D; Gassner C; Dierich MP; Stoiber H; Bánki Z
Immunol Lett; 2009 Sep; 126(1-2):85-90. PubMed ID: 19698750
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis.
Takefman DM; Sullivan BL; Sha BE; Spear GT
Virology; 1998 Jul; 246(2):370-8. PubMed ID: 9657955
[TBL] [Abstract][Full Text] [Related]
3. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).
Zhou J; Montefiori DC
Virology; 1996 Dec; 226(1):13-21. PubMed ID: 8941318
[TBL] [Abstract][Full Text] [Related]
4. Complement-mediated enhancement of HIV-1 neutralisation by anti-HLA antibodies derived from polytransfused patients.
Wilfingseder D; Spruth M; Ammann CG; Döpper S; Speth C; Dierich MP; Stoiber H
Int Arch Allergy Immunol; 2003 May; 131(1):62-72. PubMed ID: 12759492
[TBL] [Abstract][Full Text] [Related]
5. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
Vogel T; Kurth R; Norley S
J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
[TBL] [Abstract][Full Text] [Related]
6. Fc receptor but not complement binding is important in antibody protection against HIV.
Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
[TBL] [Abstract][Full Text] [Related]
7. Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.
Yang K; Lan J; Shepherd N; Hu N; Xing Y; Byrd D; Amet T; Jewell C; Gupta S; Kounga C; Gao J; Yu Q
J Virol; 2015 Sep; 89(18):9393-406. PubMed ID: 26136568
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.
Sullivan BL; Knopoff EJ; Saifuddin M; Takefman DM; Saarloos MN; Sha BE; Spear GT
J Immunol; 1996 Aug; 157(4):1791-8. PubMed ID: 8759769
[TBL] [Abstract][Full Text] [Related]
9. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
[TBL] [Abstract][Full Text] [Related]
10. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41.
Burrer R; Haessig-Einius S; Aubertin AM; Moog C
Virology; 2005 Mar; 333(1):102-13. PubMed ID: 15708596
[TBL] [Abstract][Full Text] [Related]
12. Humoral immunity to HIV-1: neutralization and beyond.
Huber M; Trkola A
J Intern Med; 2007 Jul; 262(1):5-25. PubMed ID: 17598812
[TBL] [Abstract][Full Text] [Related]
13. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
Akagi T; Kawamura M; Ueno M; Hiraishi K; Adachi M; Serizawa T; Akashi M; Baba M
J Med Virol; 2003 Feb; 69(2):163-72. PubMed ID: 12683403
[TBL] [Abstract][Full Text] [Related]
14. Immunopathogenesis and immunotherapy in AIDS virus infections.
Letvin NL; Walker BD
Nat Med; 2003 Jul; 9(7):861-6. PubMed ID: 12835706
[TBL] [Abstract][Full Text] [Related]
15. HIV and human complement: mechanisms of interaction and biological implication.
Dierich MP; Ebenbichler CF; Marschang P; Füst G; Thielens NM; Arlaud GJ
Immunol Today; 1993 Sep; 14(9):435-40. PubMed ID: 8216721
[TBL] [Abstract][Full Text] [Related]
16. Genetic and immune correlates of the HIV infection and vaccine-induced immunity. Foreword.
Füst G
Vaccine; 2008 Jun; 26(24):2949-50. PubMed ID: 18321613
[No Abstract] [Full Text] [Related]
17. Complement, Fc receptors and antibodies: a Trojan horse in HIV infection?
Stoiber H
Curr Opin HIV AIDS; 2009 Sep; 4(5):394-9. PubMed ID: 20048703
[TBL] [Abstract][Full Text] [Related]
18. The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients.
Gerencer M; Burek V; Crowe BA; Barrett NP; Dorner F
Microb Pathog; 1998 Nov; 25(5):253-66. PubMed ID: 9878454
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
20. [Induction of neutralizing antibodies against HIV-1 viruses in HLA-DQ6 mice by peptide vaccines].
Takahashi A
Hokkaido Igaku Zasshi; 1998 Mar; 73(2):147-56. PubMed ID: 9612708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
